Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Chemotherapy often causes severe side effects, limiting treatment efficacy.
• Developing targeted drug delivery systems is crucial for optimizing cancer therapy.
• Macromolecular carriers like liposomes and antibodies are common, but novel approaches are needed.

Purpose of the Study:

• To develop a novel anthracycline conjugate using a small peptide carrier for improved cancer chemotherapy.
• To investigate the efficacy and mechanism of a daunorubicin-peptide conjugate.
• To explore the potential of human calcitonin-derived peptides as drug delivery vehicles.

Main Methods:

• Synthesis of two daunorubicin-peptide conjugates: one with an acid-stable amide bond, another with an acid-labile hydrazone bond.
• In vitro cytotoxicity assays using daunorubicin-sensitive cell lines (neuroblastoma, HEK 293 T).
• Fluorescence microscopy to study cellular uptake and drug release mechanisms.

Main Results:

• The daunorubicin conjugate with an acid-labile hydrazone bond showed comparable cytotoxicity to free daunorubicin in tested cell lines.
• Fluorescence microscopy indicated that the carrier peptide facilitates cellular uptake.
• Evidence suggests intracellular drug release occurs in low-pH endosomal compartments.

Conclusions:

• A novel peptide-drug conjugate system using human calcitonin-derived peptide hCT(9-32) shows potential for targeted cancer chemotherapy.
• The acid-labile linkage is crucial for effective intracellular drug release.
• This approach may help reduce systemic side effects associated with conventional chemotherapy.